In the present study, we used the previously published Cologne cohort of 348 KEAP1/NFE2L2 mutation-enriched NSCLC to assess the capability of NQO1 IHC and a selection of monogenetic single-gene RNA tests to predict KEAP1/NFE2L2 mutations and the KEAP1/NFE2L2 pathway activation as defined by the K1N2 score. The gene discussed is KEAP1; the disease is non-small cell lung carcinoma.